3 February 2022 - update on CMA investigation
The healthcare group has issued an update on the Competition and Markets Authority investigation first announced on 23 May 2019. Following the investigation, the CMA has announced its finding that all four companies involved have infringed competition law. Alliance Pharma fundamentally disagrees with the CMA's finding and confirms that it did not participate in, or profit from, any market sharing arrangement and refutes any involvement in the alleged competition law infringement. It will be appealing the decision and the proposed fine of £7.9m at the Competition Appeal Tribunal . . .
This content is restricted to members only. We offer three packages from 1 month to a whole year of daily tips, market news and commentary, plus our monthly newsletters.
Registration is quick and simple HERE.
Already a member, log in HERE.
